214 related articles for article (PubMed ID: 32575112)
1. Direct oral anticoagulants and cancer-associated VTE: good for all, or just some?
Carrier M; Wang TF
Blood; 2020 Aug; 136(6):669-673. PubMed ID: 32575112
[TBL] [Abstract][Full Text] [Related]
2. Anticoagulation for COVID-19 Patients: A Bird's-Eye View.
Kreidieh F; Temraz S
Clin Appl Thromb Hemost; 2021; 27():10760296211039288. PubMed ID: 34595937
[TBL] [Abstract][Full Text] [Related]
3. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.
Giustozzi M; Franco L; Vedovati MC; Becattini C; Agnelli G
J Thromb Thrombolysis; 2019 Oct; 48(3):439-453. PubMed ID: 31104194
[TBL] [Abstract][Full Text] [Related]
4. Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer.
Ueyama H; Miyashita H; Takagi H; Cruz C; Burger A; Briasoulis A; Kuno T
J Thromb Thrombolysis; 2021 Jan; 51(1):102-111. PubMed ID: 32458316
[TBL] [Abstract][Full Text] [Related]
5. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis.
Mulder FI; Bosch FTM; Young AM; Marshall A; McBane RD; Zemla TJ; Carrier M; Kamphuisen PW; Bossuyt PMM; Büller HR; Weitz JI; Middeldorp S; van Es N
Blood; 2020 Sep; 136(12):1433-1441. PubMed ID: 32396939
[TBL] [Abstract][Full Text] [Related]
6. Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study.
Campello E; Spiezia L; Simion C; Tormene D; Camporese G; Dalla Valle F; Poretto A; Bulato C; Gavasso S; Radu CM; Simioni P
J Am Heart Assoc; 2020 Dec; 9(23):e018917. PubMed ID: 33222589
[TBL] [Abstract][Full Text] [Related]
7. [Factor Xa inhibitors - equivalent to low molecular weight heparin for the treatment of cancer-associated venous thromboembolism].
Magnusson P; Mattsson G
Lakartidningen; 2021 Apr; 118():. PubMed ID: 33836092
[TBL] [Abstract][Full Text] [Related]
8. Cancer is not a single disease: is it safe to extrapolate evidence from trials of direct oral anticoagulants in cancer-associated venous thromboembolism to patients with haematological malignancies?
Buka RJ; Chandra D; Sutton DJ
Br J Haematol; 2021 Apr; 193(1):194-197. PubMed ID: 33618429
[No Abstract] [Full Text] [Related]
9. Factor Xa Inhibition for the Treatment of Venous Thromboembolism Associated With Cancer: A Meta-Analysis of the Randomised Controlled Trials.
Murphy AC; Koshy AN; Farouque O; Yeo B; Raman J; Kearney L; Yudi MB
Heart Lung Circ; 2022 May; 31(5):716-725. PubMed ID: 34896013
[TBL] [Abstract][Full Text] [Related]
10. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis.
Lu X; Lin J
BMC Musculoskelet Disord; 2018 Sep; 19(1):322. PubMed ID: 30193575
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update.
Franco-Moreno A; Cabezón-Gutiérrez L; Palka-Kotlowsa M; Villamayor-Delgado M; García-Navarro M
J Thromb Thrombolysis; 2019 Apr; 47(3):409-419. PubMed ID: 30467760
[TBL] [Abstract][Full Text] [Related]
12. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
Pernod G; Joly M; Sonnet B
J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
[TBL] [Abstract][Full Text] [Related]
13. [Not Available].
Sarinayova S; Heizmann M
Praxis (Bern 1994); 2018 Jan; 107(3):145-151. PubMed ID: 29382262
[No Abstract] [Full Text] [Related]
14. Treatment of Venous Thromboembolism in Cancer. Historical Perspective and Evolving Role of the Direct Oral Anticoagulants.
Carrier M; Soff G; Le Gal G
Cancer Treat Res; 2019; 179():103-115. PubMed ID: 31317483
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis.
Rossel A; Robert-Ebadi H; Combescure C; Grosgurin O; Stirnemann J; Addeo A; Garin N; Agoritsas T; Reny JL; Marti C
PLoS One; 2019; 14(3):e0213940. PubMed ID: 30897142
[TBL] [Abstract][Full Text] [Related]
16. Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Sun G; Wu J; Wang Q; Liang Q; Jia J; Cheng K; Sun G; Wang Z
J Arthroplasty; 2019 Apr; 34(4):789-800.e6. PubMed ID: 30685261
[TBL] [Abstract][Full Text] [Related]
17. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH.
Kaatz S; Ahmad D; Spyropoulos AC; Schulman S;
J Thromb Haemost; 2015 Nov; 13(11):2119-26. PubMed ID: 26764429
[No Abstract] [Full Text] [Related]
18. A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK.
Cohen AT; Benson G; Bradbury CA; Choudhuri S; Hutchinson Jones N; Maraveyas A; Venugopal B; Young AM; Chapman C; McIntyre S; Burney D; Pollock KG; Morgan AR; Gabb PD; Alikhan R
Curr Med Res Opin; 2023 Mar; 39(3):483-495. PubMed ID: 36629478
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer.
Lee JH; Oh YM; Lee SD; Lee JS
J Korean Med Sci; 2019 Jun; 34(21):e160. PubMed ID: 31144482
[TBL] [Abstract][Full Text] [Related]
20. Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: the CARMEN study.
Sevestre MA; Belizna C; Durant C; Bosson JL; Vedrine L; Cajfinger F; Debourdeau P; Farge D;
J Mal Vasc; 2014 May; 39(3):161-8. PubMed ID: 24746736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
